These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 27396730)
1. Treatment of Multifocal Renal Cell Carcinoma in a Solitary Kidney With Nivolumab. Shinder B; Farber NJ; Mayer T; Singer EA Clin Genitourin Cancer; 2017 Feb; 15(1):e165-e167. PubMed ID: 27396730 [No Abstract] [Full Text] [Related]
2. Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab. Adra N; Cheng L; Pili R Clin Genitourin Cancer; 2017 Jun; 15(3):e517-e519. PubMed ID: 28110836 [No Abstract] [Full Text] [Related]
3. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. Joseph RW; Chatta G; Vaishampayan U Urol Oncol; 2017 Apr; 35(4):142-148. PubMed ID: 28259541 [TBL] [Abstract][Full Text] [Related]
4. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials. Buti S; Bersanelli M Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416 [No Abstract] [Full Text] [Related]
5. Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. Ruiz-Bañobre J; Abdulkader I; Anido U; León L; López-López R; García-González J APMIS; 2017 Mar; 125(3):259-263. PubMed ID: 28233446 [No Abstract] [Full Text] [Related]
6. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. Ornstein MC; Rini BI Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724 [TBL] [Abstract][Full Text] [Related]
7. Nivolumab-Induced Development of Pulmonary Sarcoidosis in Renal Cell Carcinoma. Zhang M; Schembri G Clin Nucl Med; 2017 Sep; 42(9):728-729. PubMed ID: 28737580 [TBL] [Abstract][Full Text] [Related]
8. Active and passive immunotherapy: vaccines and antibodies. Oosterwijk E; Divgi C; Bander NH BJU Int; 2007 May; 99(5 Pt B):1301-4. PubMed ID: 17441928 [No Abstract] [Full Text] [Related]
9. [Imaging of Metastastic Renal Cell Carcinoma under Therapy with Immune Checkpoint Inhibitors]. Notohamiprodjo M; Kopp HG; Bedke J Rofo; 2017 Apr; 189(4):287-292. PubMed ID: 28335045 [No Abstract] [Full Text] [Related]
10. Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma. Rouvinov K; Osyntsov L; Shaco-Levy R; Baram N; Ariad S; Mermershtain W Clin Genitourin Cancer; 2017 Dec; 15(6):e1127-e1130. PubMed ID: 28673798 [No Abstract] [Full Text] [Related]
11. Cabozantinib and nivolumab for renal cell carcinoma. Worley L Lancet Oncol; 2015 Nov; 16(15):e531. PubMed ID: 26481805 [No Abstract] [Full Text] [Related]
17. [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)]. Rexer H Urologe A; 2015 Oct; 54(10):1443-5. PubMed ID: 26350358 [No Abstract] [Full Text] [Related]